Cargando…

Anti-VEGF Treatment Strategies for Wet AMD

Over the past few years, antivascular endothelial growth factor (VEGF) therapy has become a standard treatment for neovascular age-related macular degeneration (AMD). During this time, treatment strategies have evolved from a monthly dosing schedule to individualized regimens. This paper will review...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kovach, Jaclyn L., Schwartz, Stephen G., Flynn, Harry W., Scott, Ingrid U.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3317200/ https://www.ncbi.nlm.nih.gov/pubmed/22523653 http://dx.doi.org/10.1155/2012/786870

Ejemplares similares

Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD
por: Reid, Christopher A., et al.
Publicado: (2018)

Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD
por: Batioglu, Figen, et al.
Publicado: (2015)

Bevacizumab in Wet AMD treatment: A tribute to the thirteen years of experience from the beginning of the anti-VEGF era in Romania
por: Stanca, Horia T., et al.
Publicado: (2019)

New Therapies of Neovascular AMD—Beyond Anti-VEGFs
por: Yerramothu, Praveen
Publicado: (2018)

Improving treatment provision of Wet AMD with intravitreal ranibizumab
por: Ghazala, Fadi, et al.
Publicado: (2013)

Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review
por: Khanna, Saira, et al.
Publicado: (2019)

Switching anti-VEGF agent for wet AMD: evaluation of impact on visual acuity, treatment frequency and retinal morphology in a real-world clinical setting
por: Granstam, Elisabet, et al.
Publicado: (2021)

Subretinal recombinant tissue plasminogen activator and pneumatic displacement for the management of subretinal hemorrhage occurring after anti-VEGF injections for wet AMD
por: Tognetto, Daniele, et al.
Publicado: (2011)

New Therapies of Neovascular AMD beyond Anti-VEGF Injections
por: Gahn, Greggory M., et al.
Publicado: (2018)

Epimacular brachytherapy for wet AMD: current perspectives
por: Casaroli-Marano, Ricardo P, et al.
Publicado: (2014)

Therapeutic Effect of Anti-VEGF for Age-Related Macular Degeneration in the Untreated Fellow Eye
por: Isildak, Hacer, et al.
Publicado: (2018)

Documentation of adverse events in non-commercial trials of intravitreal injection of anti-VEGF drugs to treat wet age-related macular degeneration (AMD)
por: Reeves, Barnaby C, et al.
Publicado: (2011)

Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey
por: Varano, Monica, et al.
Publicado: (2015)

Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients
por: Skelly, Adrian, et al.
Publicado: (2019)

The Architecture of Macular Neovascularizations Predicts Treatment Responses to Anti-VEGF Therapy in Neovascular AMD
por: Faatz, Henrik, et al.
Publicado: (2022)

Ranibizumab for the treatment of wet AMD: a summary of real-world studies
por: Chong, V
Publicado: (2016)

Aflibercept in wet AMD: specific role and optimal use
por: Semeraro, F, et al.
Publicado: (2013)

Aqueous humor cytokine profiling in patients with wet AMD
por: Liu, Fang, et al.
Publicado: (2016)

Incidence of ocular hypertension after intravitreal injection of anti-VEGF agents in the treatment of neovascular AMD
por: Moraru, Andreea, et al.
Publicado: (2017)

Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD
por: Fassnacht-Riederle, Heidi, et al.
Publicado: (2014)

Anti-VEGF intervention in neovascular AMD: benefits and risks restated as natural frequencies
por: Clearkin, Louis, et al.
Publicado: (2019)

VEGF-R2/Caveolin-1 Pathway of Undifferentiated ARPE-19 Retina Cells: A Potential Target as Anti-VEGF-A Therapy in Wet AMD by Resvega, an Omega-3/Polyphenol Combination
por: Courtaut, Flavie, et al.
Publicado: (2021)

A serum metabolomics study of patients with nAMD in response to anti-VEGF therapy
por: Gao, Yan, et al.
Publicado: (2020)

Expression of VEGFA‐regulating miRNAs and mortality in wet AMD
por: Blasiak, Janusz, et al.
Publicado: (2019)

Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel
por: McKibbin, M, et al.
Publicado: (2015)

Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis
por: Wu, Mingxing, et al.
Publicado: (2017)

Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD
por: Tsilimbaris, Miltiadis K., et al.
Publicado: (2016)

Topographical Analysis of the Choriocapillaris Reperfusion After Loading Anti-VEGF Therapy in Neovascular AMD
por: Viggiano, Pasquale, et al.
Publicado: (2022)

“What should I inject next?” Challenging treatment decisions in the multiple anti-VEGF: a review of publications exploring anti-VEGF switching for nAMD
por: Pikkel, Joseph, et al.
Publicado: (2017)

Psychological impact of anti-VEGF treatments for wet macular degeneration—a review
por: Senra, Hugo, et al.
Publicado: (2016)

Aflibercept in refractory wet AMD treated with ranibizumab: Anatomical and visual outcome
por: Abou-Ltaif, Sleiman
Publicado: (2016)

Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment
por: Wecker, Thomas, et al.
Publicado: (2019)

Through the Eyes of Patients: Understanding Treatment Burden of Intravitreal Anti-VEGF Injections for nAMD Patients in Norway
por: Reitan, Gudrun, et al.
Publicado: (2023)

Changes in the OCT angiographic appearance of type 1 and type 2 CNV in exudative AMD during anti-VEGF treatment
por: Faatz, Henrik, et al.
Publicado: (2019)

Evaluation of Multiple Machine Learning Models for Predicting Number of Anti-VEGF Injections in the Comparison of AMD Treatment Trials (CATT)
por: Chandra, Rajat S., et al.
Publicado: (2023)

Two Year Study of Aflibercept and Ranibizumab Intravitreal Therapy in Patients with Wet AMD
por: Luksa, Dorota, et al.
Publicado: (2021)

Anti-VEGF Drugs Influence Epigenetic Regulation and AMD-Specific Molecular Markers in ARPE-19 Cells
por: Hamid, Mohamed A., et al.
Publicado: (2021)

Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) — a meta-analysis
por: Garweg, Justus G., et al.
Publicado: (2021)

Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema
por: Gelfman, Claire M., et al.
Publicado: (2021)

Microvascular abnormalities and long-term efficacy after stereotactic radiotherapy under continued intravitreal anti-VEGF treatment for neovascular AMD
por: Hatz, Katja, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_laqk0je4ckva8hs10emfnn2ds1